Leadership Corporate Leaders

More

  • Sprint

    Sprint Nextel on Tuesday named former Embarq Corp Chief Executive Dan Hesse as its president and CEO, effective immediately.

  • Merry Christmas! The ECB's decision to inject half a trillion (trillion!) into the global marketplace (technically, they are providing what is essentially unlimited loans at a fixed fate for the next couple weeks) is definitely giving equities a shot in the arm this morning. This should put some pressure on bonds, lower LIBOR rates, and maybe prop up the dollar a bit.

  • Eli Lilly Tuesday said Sidney Taurel, the drugmaker's long-time chief executive officer, will retire on March 31 and will be succeeded by Chief Operating Officer John Lechleiter.

  • Thornburg Mortgage said Tuesday that it promoted its chief operating officer to CEO and reinstated a quarterly dividend despite ongoing turmoil in the mortgage market.

  • Novellus Systems, a supplier of equipment for making microchips, said Monday that its chief financial officer will resign around late February and join a private venture-backed company.

  • Student lender SLM -- better known as Sallie Mae -- said Friday that its executive chairman Albert Lord will take on the extra role of chief executive officer.

  • dendreon_logo_new2.jpg

    The biotech momentum players and the Dendreonites--or Dendreonians--are buzzing about the story we broke on "Power Lunch" Thursday that three members of Congress are asking the House Energy and Commerce Committee to hold a hearing about the Dendreon/Provenge saga. The shares spiked on very heavy volume.

  • Stanley O'Neal

    Merrill Lynch ousted Chairman and Chief Executive Stan O'Neal just days after reporting the biggest quarterly loss in the company's history, making him the highest-ranking casualty in the U.S. subprime mortgage crisis.

  • Cramer says it's already priced into the stock.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Novartis

    Novartis is the latest company to brand its downsizing, cost-cutting campaign. The Swiss drugmaker is calling its initiative, "Forward". It's not an acronym. So, "Forward" means Novartis is going to try to save $1.6 billion in 2010 and get rid of 2,500 employees. Although I don't think "Forward" is the word which begins with "f" that the affected workers would use to describe the initiative.

  • Goldman Sachs Chairman and Chief Executive Lloyd Blankfein is likely to get a 30 percent pay rise this year to about $70 million, despite the liquidity squeeze which has seen shares in the banking sector tumble, the Financial Times reported on its Web site.

  • underwater_67.jpg

    Last year one of our producers had the bright idea of assigning each of CNBC's beat reporters a story about seven predictions for their beat for 2007. So, now this year not only do we have to do the 8 for '08 thing for TV, but also for the blog.

  • wef_dimon_93.jpg

    In the spirit of Outlook '08, here are my predictions for 2008. We'll see how I did come this time next year. My personal favorite is number 7!!

  • The morning after the Merck annual business briefing, the analyst reviews are pouring in. For the most part, the ones that I've received at least, say it had a good beat. Only Sanford C. Bernstein's Tim Anderson says he can't dance to it. He titles a research note to clients, "Annual Business Review Uneventful--No Real Surprises, Positive Or Negative."

  • A quarter-point cut wasn't enough, he says. So what happens now?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • merck_logo.jpg

    I'm back at Merck HQ in central Jersey for the annual analyst meeting. And I must say that the reception--so far, at least--is much more hospitable and helpful than last year wen things were tense and got a little ugly. A new pr team is in place.

  • The Austrian running the world's largest food group talks about trust and the need to delegate in order for an organisation of Nestle's complexity to succeed. Peter Brabeck also hits back at critics of his decision to take the dual mandate of Chairman and CEO, whilst rebuffing journalists who write he's chosen the wrong candidate to succeed him as CEO.

  • Dow Jones, publisher of the Wall Street Journal, said Thursday that Chief Executive Richard Zannino will leave the company once its acquisition by News Corp is completed.

  • genentech_logo_1.jpg

    My inbox is flooded this morning with research notes from analysts in the wake of yesterday's FDA panel meeting on Genentech's Avastin for breast cancer. The advisory committee voted 5-4 against recommending approval of the drug for that use. The FDA usually follows the advice of its outside panels of experts, but in close votes like this one it's not unheard of for the agency to go the other way.

  • CEO Jim Cornelius

    Regular blog readers are well aware of my relentless pursuit of big CEO interviews. So, I wanted to give the backstory to a surprising CEO cancellation of a previously scheduled and confirmed interview today by Bristol-Myers Squibb. A few weeks ago, my producer Ruth and I got tentative confirmation from a Bristol spokesman that the relatively new CEO Jim Cornelius would finally do his first TV interview since taking over the company last year.